NZ334035A - Use of endokine alpha antagonists to diagnose and treat TNF-related disorders - Google Patents
Use of endokine alpha antagonists to diagnose and treat TNF-related disordersInfo
- Publication number
- NZ334035A NZ334035A NZ334035A NZ33403596A NZ334035A NZ 334035 A NZ334035 A NZ 334035A NZ 334035 A NZ334035 A NZ 334035A NZ 33403596 A NZ33403596 A NZ 33403596A NZ 334035 A NZ334035 A NZ 334035A
- Authority
- NZ
- New Zealand
- Prior art keywords
- amino acid
- endokine alpha
- acid sequence
- cytokine
- seq
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 2
- 239000002299 complementary DNA Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108700026244 Open Reading Frames Proteins 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000012163 sequencing technique Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C07K14/5255—Lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ334035A NZ334035A (en) | 1996-08-16 | 1996-08-16 | Use of endokine alpha antagonists to diagnose and treat TNF-related disorders |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ334035A NZ334035A (en) | 1996-08-16 | 1996-08-16 | Use of endokine alpha antagonists to diagnose and treat TNF-related disorders |
| PCT/US1996/013282 WO1998007880A1 (en) | 1996-08-16 | 1996-08-16 | Human endokine alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ334035A true NZ334035A (en) | 2000-09-29 |
Family
ID=22255618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ334035A NZ334035A (en) | 1996-08-16 | 1996-08-16 | Use of endokine alpha antagonists to diagnose and treat TNF-related disorders |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP0961831B1 (https=) |
| JP (1) | JP2000516474A (https=) |
| KR (1) | KR20010102191A (https=) |
| AT (1) | ATE412740T1 (https=) |
| AU (4) | AU731123B2 (https=) |
| CA (1) | CA2264200A1 (https=) |
| DE (1) | DE69637734D1 (https=) |
| DK (1) | DK0961831T3 (https=) |
| ES (1) | ES2316153T3 (https=) |
| NZ (1) | NZ334035A (https=) |
| WO (1) | WO1998007880A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001009327A2 (en) * | 1999-07-28 | 2001-02-08 | Genentech, Inc. | Method of preventing the injury or death of retinal cells and treating ocular diseases |
| US7597886B2 (en) | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
| US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
| WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US6713061B1 (en) | 1996-03-12 | 2004-03-30 | Human Genome Sciences, Inc. | Death domain containing receptors |
| US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
| US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
| US6406867B1 (en) | 1996-08-16 | 2002-06-18 | Human Genome Sciences, Inc. | Antibody to human endokine alpha and methods of use |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| WO2001040464A1 (en) * | 1999-11-30 | 2001-06-07 | Genentech, Inc. | Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization |
| US6503184B1 (en) | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| JP4485049B2 (ja) * | 1997-11-18 | 2010-06-16 | ジェネンテック， インコーポレイテッド | Ｄｎａ１９３５５ポリペプチドという腫瘍壊死因子相同体 |
| EP2357192A1 (en) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
| ES2307515T3 (es) * | 1999-06-02 | 2008-12-01 | Genentech Inc | Activacion o inhibicion de la angiogenesis y la cardiovascularizacion. |
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2413160A1 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| WO2002016411A2 (en) | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
| MXPA03010747A (es) | 2001-05-25 | 2004-03-02 | Human Genome Sciences Inc | Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. |
| EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
| EA015860B1 (ru) | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
| CA2738472A1 (en) | 2008-09-26 | 2010-04-22 | Tocagen Inc. | Gene therapy vectors and cytosine deaminases |
| SG10201509499RA (en) | 2010-11-19 | 2015-12-30 | Eisai R&D Man Co Ltd | Neutralizing anti-ccl20 antibodies |
| NL2005893C2 (nl) | 2010-12-22 | 2012-06-25 | Vanderlande Ind Bv | Systeem en werkwijze voor het bufferen van bagagestukken. |
| EP3623478A1 (en) | 2012-10-25 | 2020-03-18 | Tocagen Inc. | Retroviral vector with mini-promoter cassette |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US599817A (en) * | 1898-03-01 | Cash-register | ||
| US4433092A (en) | 1981-03-09 | 1984-02-21 | Champion Spark Plug Company | Green ceramic of lead-free glass, conductive carbon, silicone resin and AlPO4, useful, after firing, as an electrical resistor |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0148311B1 (en) * | 1983-12-26 | 1988-07-20 | Asahi Kasei Kogyo Kabushiki Kaisha | A novel physiologically active polypeptide |
| US5288852A (en) * | 1984-03-06 | 1994-02-22 | Dainippon Pharmaceutical Co., Ltd. | Human tumor necrosis factor polypeptides |
| DE3586772T2 (de) | 1984-07-24 | 1993-03-04 | Coselco Mimotopes Pty Ltd | Verfahren zur bestimmung von mimotopen. |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| EP0232262A4 (en) | 1985-08-15 | 1989-09-19 | Stauffer Chemical Co | TRYPTOPHANE GENERATING MICROORGANISM. |
| DE3650150T2 (de) | 1985-08-16 | 1995-04-27 | The Rockefeller University, New York, N.Y. | Modulator der anabolischen Aktivität und seine Verwendungen. |
| US4870163A (en) * | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
| LU86128A1 (fr) | 1985-10-18 | 1987-06-02 | Vander Poorten Henri | Procede permettant l'impression ou le revetement de ceramique simultanement a son electroformage et conduisant en monocuisson a des produits decoratifs ou techniques |
| JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
| EP0288088B1 (en) | 1987-04-24 | 1994-03-09 | Teijin Limited | Detection of tumor necrosis factor; monoclonal antibody and kit |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| ES2120949T4 (es) | 1990-06-28 | 2011-12-29 | Sanofi-Aventis Deutschland Gmbh 50% | Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo. |
| US5480971A (en) | 1993-06-17 | 1996-01-02 | Houghten Pharmaceuticals, Inc. | Peralkylated oligopeptide mixtures |
| JP4046349B2 (ja) * | 1994-11-07 | 2008-02-13 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 腫瘍壊死因子−γ |
| US5998171A (en) * | 1996-08-16 | 1999-12-07 | Human Genome Sciences, Inc. | Polynucleotides encoding human endokine alpha |
-
1996
- 1996-08-16 ES ES96928886T patent/ES2316153T3/es not_active Expired - Lifetime
- 1996-08-16 EP EP96928886A patent/EP0961831B1/en not_active Expired - Lifetime
- 1996-08-16 EP EP08018826A patent/EP2025682A3/en not_active Withdrawn
- 1996-08-16 KR KR1020017010401A patent/KR20010102191A/ko not_active Ceased
- 1996-08-16 AT AT96928886T patent/ATE412740T1/de active
- 1996-08-16 DK DK96928886T patent/DK0961831T3/da active
- 1996-08-16 WO PCT/US1996/013282 patent/WO1998007880A1/en not_active Ceased
- 1996-08-16 DE DE69637734T patent/DE69637734D1/de not_active Expired - Lifetime
- 1996-08-16 NZ NZ334035A patent/NZ334035A/xx not_active IP Right Cessation
- 1996-08-16 AU AU68478/96A patent/AU731123B2/en not_active Ceased
- 1996-08-16 JP JP10510675A patent/JP2000516474A/ja not_active Withdrawn
- 1996-08-16 CA CA002264200A patent/CA2264200A1/en not_active Abandoned
-
2001
- 2001-06-20 AU AU53937/01A patent/AU764278B2/en not_active Withdrawn - After Issue
-
2003
- 2003-10-28 AU AU2003257892A patent/AU2003257892A1/en not_active Abandoned
-
2007
- 2007-06-08 AU AU2007202630A patent/AU2007202630B8/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007202630A1 (en) | 2007-06-28 |
| ATE412740T1 (de) | 2008-11-15 |
| AU6847896A (en) | 1998-03-06 |
| WO1998007880A1 (en) | 1998-02-26 |
| EP2025682A3 (en) | 2009-06-17 |
| AU2007202630B8 (en) | 2010-08-19 |
| JP2000516474A (ja) | 2000-12-12 |
| DE69637734D1 (de) | 2008-12-11 |
| AU764278B2 (en) | 2003-08-14 |
| AU2007202630B2 (en) | 2010-04-22 |
| AU731123B2 (en) | 2001-03-22 |
| AU5393701A (en) | 2001-08-16 |
| KR20010102191A (ko) | 2001-11-15 |
| ES2316153T3 (es) | 2009-04-01 |
| CA2264200A1 (en) | 1998-02-26 |
| AU2003257892A1 (en) | 2003-11-20 |
| EP0961831A1 (en) | 1999-12-08 |
| EP0961831B1 (en) | 2008-10-29 |
| DK0961831T3 (da) | 2009-01-12 |
| EP0961831A4 (en) | 2002-06-12 |
| EP2025682A2 (en) | 2009-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ334035A (en) | Use of endokine alpha antagonists to diagnose and treat TNF-related disorders | |
| Cox | Endogenous opioid peptides: a guide to structures and terminology | |
| Weining et al. | A chicken homolog of mammalian interleukin‐1β: cDNA cloning and purification of active recombinant protein | |
| Hiraki et al. | Molecular cloning of a new class of cartilage-specific matrix, chondromodulin-I, which stimulates growth of cultured chondrocytes | |
| Wagener et al. | Primary structure of matrilin-3, a new member of a family of extracellular matrix proteins related to cartilage matrix protein (matrilin-1) and von Willebrand factor | |
| Ouellette et al. | Purification and primary structure of murine cryptdin‐1, a Paneth cell defensin | |
| CA2343655A1 (en) | Interleukin 17-like receptor protein | |
| EP0782584A1 (en) | Il-1 receptor antagonists with enhanced inhibitory activity | |
| WO1994012638A3 (en) | Interleukin-3 (il-3) multiple mutation polypeptides | |
| DE10075019I2 (de) | Neue Proteine mit TNF-Hemmender Wirkung und ihre Herstellung. | |
| CA2266439A1 (en) | Neutrokine .alpha. | |
| EP1012292A1 (en) | Ntn-2 member of tnf ligand family | |
| EP0991759A1 (en) | Ntn-2 member of tnf ligand family | |
| DE951551T1 (de) | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie | |
| MX9703476A (es) | Factor derivado de neuronas sensoriales y motoras (smdf). | |
| RU95117238A (ru) | Нуклеиновая кислота, рекомбинантная плазмида, рекомбинантный вектор, белок, синтетический пептид, химерная молекула, иммуногенная композиция, антисыворотка или антитела | |
| RU99107759A (ru) | Применение антагонистов лептина для лечения резистентности к инсулину при диабете ii типа | |
| BG102973A (en) | LIGAND RET (RetL) FOR THE STIMULATION OF THE NERVE AND RENAL GROWTH | |
| CA2378543A1 (en) | Modified human granulocyte-colony stimulating factor and process for producing same | |
| RU2002103159A (ru) | Модифицированный колониестимулирующий фактор гранулоцитов человека и способ его получения, днк, экспрессирующий вектор | |
| EP1092727A3 (en) | G-protein receptor | |
| US6447996B1 (en) | Galanin receptors, nucleic acids, transformed cells and uses thereof | |
| KR940005798A (ko) | 지방세포화 억제 인자 유도체, 그의 제조방법 및 용도 | |
| Yang et al. | Solution structure of the recombinant human oncoprotein p13 MTCP1 | |
| CA2265500A1 (en) | Novel semaphorin gene: semaphorin y |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| EXPY | Patent expired |